Claim Amendments

Please amend the claims as shown below.

1. (previously presented) A crystalline solid famciclovir form I, characterized by a XRD pattern with peaks at 15.5 and 15.9 ± 0.2 deg. 2θ, wherein the crystalline solid famciclovir contains less than about 5% wt of another famciclovir crystalline form.
2. (original) The crystalline solid famciclovir of claim 1, further characterized by a XRD pattern with peaks at 8.2, 10.4, 14.5, 17.0, 17.7, 19.5, 20.6, 21.1, 22.3, 23.0, 23.9, 24.4, 25.6, 26.5, 28.6, 29.0 and 32.6 ± 0.2 deg. 2θ.
3. (currently amended) The crystalline solid famciclovir of claim 2, ~~further characterized by~~ a wherein the XRD pattern is as substantially depicted in Fig. 1.
4. (canceled)
5. (previously presented) The crystalline solid famciclovir of any one of claims 1-3, wherein the crystalline solid famciclovir contains less than about 5% wt of form II.
6. (currently amended) The crystalline solid famciclovir of any one of claims 1-3 ~~claim 5~~, wherein the crystalline solid famciclovir contains less than about 1% wt of another famciclovir crystalline form.
7. (currently amended) The crystalline solid famciclovir of claim 5 [[[6]]], wherein the crystalline solid famciclovir contains less than about 1% wt of form II.
8. (previously presented) A crystalline solid famciclovir form II, characterized by a XRD pattern with peaks at 16.2 and 16.4 ± 0.2 deg. 2θ, wherein the crystalline solid famciclovir contains less than about 5% wt of another famciclovir crystalline form.
9. (currently amended) The crystalline solid famciclovir of claim 8, further characterized by ~~a~~ the XRD pattern ~~with~~ having peaks at 8.3, 14.6, 17.8, 19.7, 20.7, 21.2, 24.5 and 25.6 ± 0.2 deg. 2θ.
10. (currently amended) The crystalline solid famciclovir of claim 9, ~~further characterized by~~ a wherein the XRD pattern is as substantially depicted in Fig. 2.
11. (currently amended) ~~A crystalline~~ Crystalline solid famciclovir methanol solvate, characterized by a XRD pattern with peaks at 6.6 and 13.0 ± 0.2 deg. 2θ.

12. (currently amended) The crystalline solid famciclovir solvate of claim 11, further characterized by ~~a~~ the XRD pattern ~~with~~ having peaks at 15.9, 16.7, 18.4, 19.6, 24.5, 25.0 and 26.2 ± 0.2 deg. 2θ.

13. (currently amended) The crystalline solid famciclovir solvate of claim 12, ~~further characterized by a~~ wherein the XRD pattern is as substantially depicted in Fig. 3.

14. (currently amended) The crystalline solid famciclovir solvate of claim 11, containing less than about 5% wt of another famciclovir crystalline form ~~wherein the crystalline solid famciclovir solvate is a methanol solvate~~.

15. (currently amended) ~~The crystalline~~ Crystalline solid famciclovir ~~solvate of claim 11, wherein the crystalline solid famciclovir solvate is an~~ ethanol solvate, characterized by a XRD pattern having peaks at 6.6 and 13.0 ± 0.2 deg. 2θ.

16. (original) Crystalline solid famciclovir methanol solvate.

17. (original) Crystalline solid famciclovir ethanol solvate.

18. (original) A process for preparing the crystalline solid famciclovir of claim 1, comprising the steps of:

    a) triturating an anhydrous famciclovir form in an organic solvent selected from the group consisting of isopropyl alcohol, acetonitrile, and diethylether; and

    b) isolating the crystalline solid famciclovir of claim 1.

19. (original) A crystalline solid famciclovir form I prepared by triturating an anhydrous famciclovir form in an organic solvent selected from the group consisting of isopropyl alcohol, acetonitrile, and diethylether.

20. (currently amended) A process for preparing ~~the~~ crystalline solid famciclovir form I ~~of claim 1~~, characterized by a XRD pattern with peaks at 15.5 and 15.9 ± 0.2 deg. 2θ, comprising the steps of:

    a) heating crystalline solid famciclovir methanol or ethanol solvate, characterized by a XRD pattern with peaks at 6.6 and 13.0 ± 0.2 deg. 2θ, ~~of claim 11~~ to about 40° C to about 90° C; and

    b) isolating the crystalline solid famciclovir form I ~~of claim 1~~.

21. (currently amended) The process of claim 20, wherein the heating of the crystalline solid famciclovir methanol or ethanol solvate ~~of claim 11~~ is performed at a temperature of about 60° C to about 70° C.

22. (currently amended) A process for preparing ~~the~~ crystalline solid famciclovir form I ~~of claim 1~~, characterized by a XRD pattern with peaks at 15.5 and 15.9 ± 0.2 deg. 2θ, comprising the steps of:

a) heating famciclovir monohydrate to about 40° C to about 80° C; and

b) isolating the crystalline solid famciclovir ~~of~~ form I.

23. (previously presented) The process of claim 22, wherein step a) is performed by heating a mixture of the famciclovir monohydrate and crystalline solid famciclovir form I characterized by a XRD pattern with peaks at 15.5 and 15.9 ± 0.2 deg. 2θ.

24. (original) The process of claim 22, wherein the heating of famciclovir monohydrate is performed at a temperature of about 60° C to about 70° C.

25. (currently amended) A process for preparing ~~the~~ crystalline solid famciclovir form I ~~of claim 1~~, characterized by a XRD pattern with peaks at 15.5 and 15.9 ± 0.2 deg. 2θ, comprising the steps of:

a) heating ~~the~~ crystalline solid famciclovir form II, characterized by a XRD pattern with peaks at 16.2 and 16.4 ± 0.2 deg. 2θ, ~~of claim 8~~ to about 40° C to about 90° C; and

b) isolating the crystalline solid famciclovir form I ~~of claim 1~~.

26. (currently amended) The ~~processes~~ process of any one of claims ~~18,~~ 20, 22 and 25, wherein the isolated crystalline solid famciclovir ~~contain~~ contains less than about 5% wt of other famciclovir crystalline forms.

27. (currently amended) The ~~processes~~ process of any one of claims ~~18,~~ 20, 22 and 25, wherein the isolated crystalline solid famciclovir contains less than about 5% wt of crystalline famciclovir form II.

28. (currently amended) The process of claim 26, wherein the isolated crystalline solid famciclovir ~~contain~~ contains less than about 1% wt of other famciclovir crystalline forms.

29. (previously presented) The process of claim 28, wherein the isolated crystalline solid famciclovir contains less than about 1% wt of crystalline famciclovir form II.

30. (currently amended) A process for preparing the crystalline solid famciclovir of claim 1, comprising the steps of:

a) providing a solution of famciclovir in an organic solvent selected from the group consisting of dichloromethane, chloroform, acetonitrile, ~~ethylacetate,~~ acetone, THF,

diethyl ether/dichloromethane mixture, dichloromethane/toluene mixture, ethylacetate/toluene mixture, acetonitrile/toluene mixture and dimethylacetamide,

b) cooling the solution, and

c) isolating the crystalline solid famciclovir of claim 1.

31. (currently amended) A process for preparing the crystalline solid famciclovir of claim 8, comprising the steps of:

a) providing a solution of famciclovir in ethanol,

b) cooling the solution whereby the crystalline solid famciclovir ~~form II~~ of claim 8 crystallizes, and

c) isolating the crystalline solid famciclovir of claim 8.

32. (currently amended) A process for preparing a mixture of crystalline solid famciclovir form II, characterized by a XRD pattern with peaks at 16.2 and 16.4 ± 0.2 deg. 2θ, and crystalline solid famciclvir form I, characterized by a XRD pattern with peaks at 15.5 and 15.9 ± 0.2 deg. 2θ ~~of claim 1~~, comprising the steps of:

a) providing a solution of famciclovir in an organic solvent selected from the group consisting of chloroform, ~~ethylacetate,~~ diethyl ether/dichloromethane mixture, tetrahydrofuran, acetonitrile/toluene mixture, dimethylacetamide and isopropanol,

b) cooling the solution, and

c) isolating the mixture of the crystalline solid famciclovir form II, ~~characterized by a XRD pattern with peaks at 16.2 and 16.4 ± 0.2 deg. 2θ,~~ and the crystalline solid famciclovir form I ~~of claim 1~~.

33. (currently amended) A process for preparing the crystalline solid famciclovir methanol solvate of claim 11, comprising the steps of:

a) triturating an anhydrous famciclovir in methanol; and

b) isolating the crystalline solid famciclovir methanol solvate ~~of claim 11~~.

34. (currently amended) A process of preparing a mixture of the crystalline solid famciclovir ethanol solvate of claim 15 ~~11~~ and the crystalline solid famciclovir of claim 1, comprising the steps of:

a) triturating an anhydrous famciclovir in ethanol; and

b) isolating the mixture of the crystalline solid famciclovir ethanol solvate of claim 15 ~~11~~ and the crystalline solid famciclovir of claim 1.

35. (currently amended) A process of preparing a crystalline solid famciclovir monohydrate, comprising the steps of:

a) providing a solution of famciclovir in an ~~organic solvent selected from the group consisting of acetonitrile, ethyl acetate, acetone, isopropyl alcohol, tetrahydrofuran,~~ ethanol/water mixture, DMF/water mixture, DMA/water mixture, acetonitrile/water mixture, methanol/water mixture, tetrahydrofuran/water mixture, and/or ~~and~~ isopropyl alcohol/water mixture; and

b) cooling the solution; and

c) isolating the crystalline solid famciclovir monohydrate.

36. (currently amended) A process for preparing a mixture of the crystalline solid famciclovir ethanol solvate of claim 15 ~~11~~ and crystalline solid famciclovir monohydrate, comprising the steps of:

a) triturating anhydrous famciclovir in an ~~organic solvent selected from the group consisting of isopropyl alcohol and~~ ethanol/water mixture; and

b) isolating the mixture of the crystalline solid famciclovir ethanol solvate ~~of claim 11~~ and crystalline solid famciclovir monohydrate.

37. (previously presented) A solid pharmaceutical composition comprising the crystalline solid famciclovir of claim 1 and a pharmaceutically-acceptable excipient.

38. (previously presented) The solid pharmaceutical composition of claim 37, wherein the crystalline solid famciclovir of claim 1 contains less than about 1% wt of another famciclovir crystalline form.

39. (previously presented) A solid pharmaceutical composition comprising the crystalline solid famciclovir of claim 8 and a pharmaceutically-acceptable excipient.

40. (previously presented) The solid pharmaceutical composition of claim 39, wherein the crystalline solid famciclovir of claim 8 contains less than about 1% wt of another famciclovir crystalline form.

41. (currently amended) A solid pharmaceutical composition comprising a crystalline solid famciclovir methanol or ethanol solvate of claim 11 or 15 and a pharmaceutically-acceptable excipient, wherein the crystalline solid famciclovir methanol or ethanol solvate ~~of claim 11~~ contains less than about 5% wt of another famciclovir crystalline form.

42. (currently amended) The solid pharmaceutical composition of claim 41, wherein the crystalline solid famciclovir methanol or ethanol solvate ~~of claim 11~~ contains less than about 1% wt of another famciclovir crystalline form.

43. (previously presented) A method of treating a human in need of treatment with famciclovir comprising administering to the human the pharmaceutical composition of any one of claims 37-42.

44. (new) The crystalline solid famciclovir ethanol solvate of claim 15, further characterized by the XRD pattern having peaks at 15.9, 16.7, 18.4, 19.6, 24.5, 25.0 and 26.2 ± 0.2 deg. 2θ.

45. (new) The crystalline solid famciclovir ethanol solvate of claim 15, containing less than about 5% wt of another famciclovir crystalline form.

46. (new) The crystalline solid famciclovir ethanol solvate of claim 45, containing less than about 1% wt of another famciclovir crystalline form.

47. (new) The crystalline solid famciclovir methanol solvate of claim 14, containing less than about 1% wt of another famciclovir crystalline form.

48. (new) The process of claim 18, wherein the isolated crystalline solid famciclovir contains less than about 5% wt of other famciclovir crystalline forms.

49. (new) The process of claim 18, wherein the isolated crystalline solid famciclovir contains less than about 5% wt of crystalline famciclovir form II.

50. (new) The process of claim 48, wherein the isolated crystalline solid famciclovir contains less than about 1% wt of other famciclovir crystalline forms.

51. (new) The process of claim 49, wherein the isolated crystalline solid famciclovir contains less than about 1% wt of crystalline famciclovir form II.